Nakopoulou Lydia, Panayotopoulou Effie G, Giannopoulou Ioanna, Tsirmpa Ioanna, Katsarou Sophia, Mylona Eleni, Alexandrou Paraskevi, Keramopoulos Antonios
Department of Pathology, Medical School, University of Athens, Athens, Greece.
J Clin Pathol. 2007 Jul;60(7):808-15. doi: 10.1136/jcp.2006.037838.
Breast cancer is a genetically complex disease, which involves the accumulation of various structural and numerical chromosomal aberrations.
To assess the numerical status of chromosomes 16 and X by interphase cytogenetics, in 114 women with primary invasive breast carcinomas, in relation to clinicopathological parameters, patients' overall survival and indices of cell growth (c-erbB-2, topoisomerase IIalpha (topoIIalpha)) and cell survival (caspase-3, bcl-2).
Chromogenic in situ hybridisation with pericentromeric probes was performed for molecular analysis, while oestrogen and progesterone receptors, cerbB-2, topoIIalpha, caspase-3 and bcl-2 expression was immunohistochemically detected (ABC/HRP). The results were statistically assessed by univariate and multivariate analyses.
Polysomy of chromosomes 16 and X was detected as the predominant aberration (73.7% and 57.9%, respectively). Gain of chromosome 16 copies was associated with high nuclear grade (p = 0.009), increased tumour size (p = 0.041), advanced stage (p = 0.002), the expression of topoIIalpha (p = 0.005) and worse overall survival by multivariate analysis (p = 0.032). Chromosome X polysomy was increased in ductal carcinomas of high histological grade (p = 0.008), in high nuclear grade tumours (p = 0.001), and was associated with the expression of topoIIalpha (p = 0.005), loss of caspase-3 (p = 0.036) and impaired prognosis of ductal carcinomas (p = 0.041).
Polysomy of chromosomes 16 and X was reported as the predominant alteration in phenotypically aggressive breast tumours, characterised by poor differentiation, increased growth potential and impaired prognosis, whereas gain of chromosome X in particular is probably implicated in cell survival.
乳腺癌是一种基因复杂的疾病,涉及各种结构和数量染色体畸变的积累。
通过间期细胞遗传学评估114例原发性浸润性乳腺癌女性患者16号和X染色体的数量状态,并分析其与临床病理参数、患者总生存期以及细胞生长指标(c-erbB-2、拓扑异构酶IIα(topoIIα))和细胞存活指标(半胱天冬酶-3、bcl-2)的关系。
采用着丝粒周围探针进行显色原位杂交进行分子分析,同时采用免疫组织化学法(ABC/HRP)检测雌激素和孕激素受体、cerbB-2、topoIIα、半胱天冬酶-3和bcl-2的表达。通过单因素和多因素分析对结果进行统计学评估。
检测到16号和X染色体多体性为主要畸变(分别为73.7%和57.9%)。16号染色体拷贝数增加与高核分级(p = 0.009)、肿瘤大小增加(p = 0.041)、晚期(p = 0.002)、topoIIα表达(p = 0.005)以及多因素分析显示的较差总生存期(p = 0.032)相关。X染色体多体性在高组织学分级的导管癌(p = 0.008)、高核分级肿瘤(p = 0.001)中增加,并且与topoIIα表达(p = 0.005)、半胱天冬酶-3缺失(p = 0.036)以及导管癌预后不良(p = 0.041)相关。
16号和X染色体多体性被报道为表型侵袭性乳腺癌的主要改变,其特征为分化差、生长潜能增加和预后不良,而特别是X染色体增加可能与细胞存活有关。